Zynerba Pharmaceuticals, Inc.·4

Sep 14, 4:14 PM ET

Sebree Terri B 4

4 · Zynerba Pharmaceuticals, Inc. · Filed Sep 14, 2023

Insider Transaction Report

Form 4
Period: 2023-09-12
Transactions
  • Award

    Common Stock

    2023-09-12+45,000608,642 total
  • Sale

    Common Stock

    2023-09-13$1.33/sh12,401$16,440596,241 total
Footnotes (2)
  • [F1]On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 45,000 performance-based restricted stock awards granted in a prior year.
  • [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES